ResearchBib Share Your Research, Maximize Your Social Impacts
Sign for Notice Everyday Sign up >> Login

LIPID HOMEOSTASIS PECULARITIES IN ISCHEMIC HEART DISEASE PATIENTS WITH HEART FAILURE SYMPTOMS, DIABETES MELLITUS 2 TYPE AND METABOLIC SYNDROME DEPENDING ON MEDICATION PECULIARITIES

Journal: The Journal of V.N. Karazin Kharkiv National University, series "Medicine" (Vol.15, No. 15)

Publication Date:

Authors : ;

Page : 79-84

Keywords : ischemic heart disease; heart failure; diabetes mellitus; metabolic syndrome; ACE inhibitors; β-blockers; general cholesterol; lipoproteids of low density; lipoproteids of very low density; lipoproteids of high density; atherogeneity;

Source : Downloadexternal Find it from : Google Scholarexternal

Abstract

91 patients have been examined to study the effectiveness of (ACE inhibitor) lysinoprile in various doses including its combination with carvedilol β-blocker as a complex treatment in ischemic heart disease patients with hert failure symptoms, diabetes mellitus 2 type (D) and metabolic syndrome (MS). The conclusion has been made that doses of lysinopril and carvedilol as a complex therapy in ischemic heart disease patients with hert failure symptoms, diabetes mellitus 2 type (D) and metabolic syndrome (MS) has a definitely positive effect concerning normalization of general cholesterol level (CH), triglycerids (TG), cholesterol lipoproteid of low density (CH-LPLD). Increasing lysinoprile dose allows to improve the level of CH-LPLD and lipoproteids of very low density (CH-LPVLD), and carvedilol promotes the reduction of CH, TG, CH-LPLD, CH -LPVLD levels. Combination of lysinoprile 2,5-5,0 mg with carvedilol 37,5-50,0 mg permits to increase the level of CH lipoproteids of high density.

Last modified: 2017-01-08 04:22:00